Cellosaurus logo
expasy logo

Cellosaurus 624-mel (CVCL_8054)

[Text version]
Cell line name 624-mel
Synonyms 624-MEL; 624 MEL; 624 Mel; 624 mel; 624mel; 624MEL; 624; Mel-624; Mel624; MEL624
Accession CVCL_8054
Resource Identification Initiative To cite this cell line use: 624-mel (RRID:CVCL_8054)
Comments From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA.
Omics: Deep exome analysis.
Omics: HLA class I peptidome analysis by proteomics.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: Metastatic; Not specified.
Sequence variations
HLA typing Source: PubMed=15592718
Class I
HLA-AA*02:01,03:01
HLA-BB*07:02,14:01
HLA-CC*07:02,08:02
Class II
HLA-DPDPB1*15:01,20:01
HLA-DQDQB1*03:01:01,02:01
HLA-DRDRB1*04:01,07:01

Source: PubMed=26589293
Class I
HLA-AA*02:01,03:01
HLA-BB*07:02,14:02
HLA-CC*07:02,08:02
Disease Melanoma (NCIt: C3224)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_A1DV (624-mel/A31)CVCL_C586 (624.28 Mel)CVCL_C588 (624.38 Mel)
CVCL_0V14 (Mel501A)CVCL_RA30 (Mel624-CMV-hNIS-Neo)CVCL_RA31 (Mel624-CMV-hNIS-Neo/eGFP-Puro)
CVCL_RA32 (Mel624-hNIS-Neo)
Sex of cell Male
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): ESTDAB; Genomics_Center_BCF_Technion; PubMed=25877200

Markers:
AmelogeninX,Y
CSF1PO10
D3S135814,16
D5S81812
D7S82010,12
D8S117912 (PubMed=25877200)
12,15 (Genomics_Center_BCF_Technion)
D13S31710,13
D16S53914
D18S5116
D21S1129
FGA23,24 (Genomics_Center_BCF_Technion)
24 (ESTDAB; PubMed=25877200)
Penta D9
Penta E7,13
TH019.3
TPOX8,10
vWA18

Run an STR similarity search on this cell line
Publications

PubMed=8027550; DOI=10.4049/jimmunol.153.3.1225
Marincola F.M., Shamamian P., Alexander R.B., Gnarra J.R., Turetskaya R.L., Nedospasov S.A., Simonis T.B., Taubenberger J.K., Yannelli J.R., Mixon A., Restifo N.P., Herlyn M., Rosenberg S.A.
Loss of HLA haplotype and B locus down-regulation in melanoma cell lines.
J. Immunol. 153:1225-1237(1994)

PubMed=8081556; DOI=10.1097/00002371-199407000-00002
Marincola F.M., Shamamian P., Simonis T.B., Abati A.D., Hackett J.A., O'Dea T., Fetsch P.A., Yannelli J.R., Restifo N.P., Mule J.J., Rosenberg S.A.
Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.
J. Immunother. Emphasis Tumor Immunol. 16:13-23(1994)

PubMed=8537970; DOI=10.1093/jnci/88.2.100
Restifo N.P., Marincola F.M., Kawakami Y., Taubenberger J.K., Yannelli J.R., Rosenberg S.A.
Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
J. Natl. Cancer Inst. 88:100-108(1996)

PubMed=9759882; DOI=10.4049/jimmunol.161.7.3596
Wang R.-F., Johnston S.L., Zeng G., Topalian S.L., Schwartzentruber D.J., Rosenberg S.A.
A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames.
J. Immunol. 161:3596-3606(1998)

PubMed=10048982; DOI=10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A
Cormier J.N., Panelli M.C., Hackett J.A., Bettinotti M.P., Mixon A., Wunderlich J.R., Parker L.L., Restifo N.P., Ferrone S., Marincola F.M.
Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model.
Int. J. Cancer 80:781-790(1999)

PubMed=10754339; DOI=10.4049/jimmunol.164.8.4382
Panelli M.C., Bettinotti M.P., Lally K., Ohnmacht G.A., Li Y., Robbins P.F., Riker A., Rosenberg S.A., Marincola F.M.
A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12.
J. Immunol. 164:4382-4392(2000)

PubMed=15467732; DOI=10.1038/sj.onc.1208152
Tanami H., Imoto I., Hirasawa A., Yuki Y., Sonoda I., Inoue J., Yasui K., Misawa-Furihata A., Kawakami Y., Inazawa J.
Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Oncogene 23:8796-8804(2004)

PubMed=15592718; DOI=10.1007/s00262-004-0561-5
Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A., Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G., Garrido F.
High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity.
Cancer Immunol. Immunother. 54:141-148(2005)

PubMed=19340423; DOI=10.1007/s00262-009-0701-z
Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T., Ruiz-Cabello F., Garrido F., Garcia-Lora A.
HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank.
Cancer Immunol. Immunother. 58:1507-1515(2009)

PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006
Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L., Borg A., Pawelec G., Guldberg P.
Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RARbeta signaling.
Mol. Cancer Res. 11:1166-1178(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)

PubMed=26589293; DOI=10.1186/s13073-015-0240-5
Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C.
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Genome Med. 7:118.1-118.7(2015)

PubMed=27600516; DOI=10.1007/s00262-016-1897-3
Gloger A., Ritz D., Fugmann T., Neri D.
Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
Cancer Immunol. Immunother. 65:1377-1393(2016)

Cross-references
Cell line databases/resources cancercelllines; CVCL_8054
CGH-DB; 9301-4
ESTDAB; ESTDAB-049
Anatomy/cell type resources BTO; BTO:0002951
Biological sample resources BioSample; SAMN03471309
CRISP screens repositories BioGRID_ORCS_Cell_line; 754
Chemistry resources ChEMBL-Cells; CHEMBL3885941
PharmacoDB; 624mel_23_2019
PubChem_Cell_line; CVCL_8054
Encyclopedic resources Wikidata; Q54604356
Experimental variables resources EFO; EFO_0006359
Gene expression databases ArrayExpress; E-MTAB-2706
GEO; GSM206438
GEO; GSM274692
Polymorphism and mutation databases Cosmic; 876683
Cosmic; 905214
Cosmic; 1303044
Cosmic; 1559441
Cosmic; 2163793
Sequence databases EGA; EGAS00001000610
EGA; EGAS00001002554
Entry history
Entry creation04-Apr-2012
Last entry update30-Jan-2024
Version number31